GLP-1 Medicare Part D spending statistics 2026

Medicare Part D is the federal prescription drug benefit for people with Medicare. GLP-1 stands for glucagon-like peptide-1, a hormone that helps regulate blood sugar and appetite. GLP-1 receptor agonists are medicines that mimic this hormone. Semaglutide is the active ingredient in Ozempic, Rybelsus, and Wegovy. Tirzepatide is the active ingredient in Mounjaro and Zepbound. These medicines are approved for different uses, including type 2 diabetes and chronic weight management. The Centers for Medicare & Medicaid Services, often shortened to CMS, publishes annual spending data for Medicare Part D. The latest annual file covers calendar year 2023. CMS also publishes newer spending figures for specific medicines as part of the Medicare Drug Price Negotiation Program. The most recent combined figure for Ozempic, Rybelsus, and Wegovy covers the 12 months from November 1, 2023, through October 31, 2024. During that period, the three brands together accounted for $14.43 billion in gross Part D prescription drug costs and were used by about 2.287 million Part D enrollees. This spending figure is gross covered prescription drug cost. It includes Medicare, plan, and beneficiary payments reported on claims, but it does not subtract confidential manufacturer rebates or other price concessions. It should not be read as the government's final net cost or as the amount a person paid at the pharmacy. The figure also combines three brands used for different indications. Ozempic and Rybelsus are commonly prescribed for type 2 diabetes. Wegovy has FDA-approved uses that include chronic weight management and reduction of major adverse cardiovascular events, often shortened to MACE, in certain adults with established cardiovascular disease and overweight or obesity.

On July 1, 2026, CMS launched the Medicare GLP-1 Bridge. This is a temporary demonstration program running through December 31, 2027. It allows eligible Medicare Part D beneficiaries to access certain GLP-1 medicines for weight management at a $50 monthly copay. The Bridge is not ordinary Part D coverage. CMS says it operates outside Part D's coverage and payment flow. That means the Part D deductible does not apply to Bridge fills,; however, the $50 copay does not count toward true out-of-pocket costs, often shortened to TrOOP, or toward the Part D out-of-pocket threshold. The 2026 Part D out-of-pocket threshold is $2,100. Low-Income Subsidy cost-sharing also does not apply to the Bridge copay. CMS lists Wegovy, Foundayo, and the KwikPen version of Zepbound as eligible products for the Bridge when prescribed for the demonstration's covered weight-management use. A person already eligible for a GLP-1 through standard Part D coverage for a covered use, such as type 2 diabetes, does not move to the Bridge simply because its $50 copay looks lower. The Bridge was created for certain people seeking treatment to reduce excess weight or maintain weight reduction who would not otherwise have Part D access.

The $14.43 billion figure works out to roughly $6,308 per user across the selection period. That is a useful scale marker, but it is not an average annual patient invoice. The group combines three brands, different formulations, different clinical uses, and people who may have had different numbers of fills. It also uses gross claim costs rather than the confidential net prices Medicare and plans may pay after rebates. For someone choosing whether to start or continue treatment, the better questions are narrower. Is my medicine covered for my diagnosis and intended use? Is there a prior authorization requirement? What will the pharmacy quote after my plan processes the claim? If weight management is the goal, do I meet the current Bridge criteria? If access changes, what is the plan for maintaining treatment or managing a pause?

Clinical trials help put access decisions in context. If a medicine is difficult to afford or coverage ends, stopping can matter because these treatments often work as ongoing therapy rather than a short course. In STEP 1, a 68-week trial of once-weekly semaglutide 2.4 mg in adults with overweight or obesity who did not have diabetes, average weight change was negative 14.9 percent with semaglutide and negative 2.4 percent with placebo, both alongside lifestyle intervention. Put simply, a person starting at 200 pounds would translate that average to about 30 pounds lost with semaglutide versus about 5 pounds with placebo. Individual results varied widely. In SURMOUNT-1, a 72-week trial in adults with overweight or obesity without diabetes, average weight change with tirzepatide was negative 15.0 percent, negative 19.5 percent, and negative 20.9 percent across the three studied doses, compared with negative 3.1 percent with placebo. At the highest studied dose, that is roughly 42 pounds from a 200-pound starting weight on average, not a promise that every person will lose that amount. Gastrointestinal side effects were common, particularly during dose escalation.

Stopping treatment deserves an equally direct conversation. In the STEP 1 extension, participants who stopped semaglutide after week 68 regained 11.6 percentage points of body weight over the next year, or about two-thirds of the weight they had lost on average. Their cardiometabolic improvements also moved back toward baseline. This does not mean someone must stay on a medicine forever. It means a clinician and patient should discuss a realistic maintenance plan before coverage, cost, or supply forces a sudden stop.

FDA-approved GLP-1 medicines have product-specific warnings, contraindications, and side effects. Common issues include nausea, vomiting, diarrhea, constipation, and abdominal discomfort. The current Wegovy label also includes serious warnings and precautions that warrant discussion with a clinician or pharmacist, including thyroid C-cell tumor risk, pancreatitis, gallbladder disease, kidney injury related to dehydration, and low blood sugar risk when used with certain diabetes medicines. On January 13, 2026, FDA said its review did not identify increased risk of suicidal ideation or behavior with GLP-1 receptor agonists and requested removal of that warning from affected labels. That finding does not replace individualized mental-health care or make it appropriate to ignore new or worsening mood symptoms. FDA also warns that compounded or otherwise unapproved GLP-1 products are not reviewed by FDA for safety, effectiveness, or quality before marketing. As of May 31, 2026, FDA had received 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. Reports alone cannot prove the medicine caused an event, and FDA says underreporting is likely.

Before your next prescriber, pharmacist, or plan call, gather the facts that determine access rather than relying on an online price estimate. Start with the exact brand, formulation, and intended use. Semaglutide alone is not enough for a coverage question because Ozempic, Rybelsus, and Wegovy are distinct products with different labels and forms. The same applies to tirzepatide products such as Mounjaro and Zepbound. Keep a simple one-page record with your Part D plan name, member ID, pharmacy, and whether you have Extra Help or another subsidy. Include the exact medication and form prescribed, such as pen, tablet, vial, or KwikPen. Note the diagnosis and FDA-approved purpose your prescriber is documenting. Track the prior authorization status, date submitted, decision date, and any requested records. Record your pharmacy's processed claim price, do not simply a cash price seen online. Note any side effects, missed doses, supply interruptions, and questions for your clinician. Have a plan for what to do if the medicine becomes unaffordable or is no longer covered.

For the Medicare GLP-1 Bridge, ask whether your prescription is being submitted for the demonstration's weight-management use and whether you meet its clinical criteria. CMS says a prescriber must submit both a prescription and a prior authorization request. Medicare beneficiaries can also use Medicare.gov's Bridge information or call 1-800-MEDICARE for program help. Useful questions for a clinician or pharmacist include: What is this medicine approved to treat in my case? Is my request going through standard Part D or the Medicare GLP-1 Bridge? What prior authorization evidence will be needed? What side effects should prompt a call rather than waiting for the next visit? Could my other medicines raise the risk of low blood sugar or dehydration? If I need to stop or pause treatment, what follow-up plan makes sense?